MERS-CoV‒Specific T-Cell Responses in Camels after Single MVA-MERS-S Vaccination.

Content Provider	Europe PMC
Author	Meyer zu Natrup, Christian Schünemann, Lisa-Marie Saletti, Giulietta Clever, Sabrina Herder, Vanessa Joseph, Sunitha Rodriguez, Marina Wernery, Ulrich Sutter, Gerd Volz, Asisa
Copyright Year	2023
Abstract	We developed an ELISPOT assay for evaluating Middle East respiratory syndrome coronavirus (MERS-CoV)‒specific T-cell responses in dromedary camels. After single modified vaccinia virus Ankara-MERS-S vaccination, seropositive camels showed increased levels of MERS-CoV‒specific T cells and antibodies, indicating suitability of camel vaccinations in disease-endemic areas as a promising approach to control infection.
ISSN	10806040
Journal	Emerging Infectious Diseases
Volume Number	29
PubMed Central reference number	PMC10202854
Issue Number	6
PubMed reference number	37209676
e-ISSN	10806059
DOI	10.3201/eid2906.230128
Language	English
Publisher	Centers for Disease Control and Prevention
Publisher Date	2023-06-01
Access Restriction	Open
Rights License	Emerging Infectious Diseases is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
Subject Keyword	MERS-CoV Middle East respiratory syndrome coronavirus coronavirus viruses dromedary camels T-cell responses ELISPOT assay MVA modified vaccinia virus Ankara MVA-MERS-S MVA expressing full-length MERS-CoV spike protein as antigen vaccination respiratory infections spike protein zoonoses Dubai
Content Type	Text
Resource Type	Article
Subject	Infectious Diseases Epidemiology Microbiology (medical)